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Suppression of bacterial growth that persists
after short exposure of bacteria to antimicro-
bial agents, called the postantibiotic effect
(PAE), has been observed both in vitro and
in vivo. Duration, and even presence or absence
of PAE depends upon the organism, the
antimicrobial agent and the environmental
conditions used for measuring the effect (Craig,
1991). The most important factors contributing
to PAE include concentration, exposure time
and mode of action of the tested drug, type
of organism, inoculum size, and type of
growth medium, and growth phase (see Craig
& Gudmundsson, 1991). Despite the recog-
nition of PAE many years ago by Bigger
(1944), and then by Eagle, Fleischman &
Musselman (1950), the mechanism by which it
occurs remains to be elucidated. Possible
mechanisms include non-lethal damage in-
duced by the antimicrobial agent and drug
persistence at the binding site (Craig &
Gudmundsson, 1991). PAEs are multiple,
including delayed recovery of proteins with and
without enzyme activities, prolonged changes
in cell morphology, metabolic alteration,
modifications of generation times, suscepti-
bility to phagocytosis and altered susceptibility
to antibiotics after re-exposure. Many of these
effects are probably linked (Mackenzie &
Gould, 1993).
Altered susceptibility to polymorphonuclear
(PMN) cells during the PAE phase is known as
the post antibiotic leucocyte effect (PALE)
(McDonald, Pruul & Wetherall, Bayer & Tu,
1990; Pruul & McDonald, 1990; Bayer et al.,
1991). PALE was found to be both strain- and
drug-dependent. In Escherichia coli aminogly-
cosides and macrolides (protein synthesis
inhibitors) displayed greater PALE than the
cell-wall acting /?-lactam antibiotics (McDon-
ald et al., 1983). Erythromycin increased the
susceptibility of Streptococcus pneumoniae
to the bactericidal activity of human PMNs
but decreased that of E. coli. Exposure to
roxithromycin increased opsonization and
phagocytosis in S. pneumoniae but not in
Streptococcus pyogenes (Gemmell & McLeod,
1992). Erythromycin and to a lesser extent
azithromycin increased the susceptibility of
streptococci to the killing activity of human
PMNs not only during the PAE phase but
also after recovery (Ramadan et al., 1994).
Erythromycin and roxithromycin but not
azithromycin altered opsonization and in-
creased the susceptibility of Staphylococcus
aureus to phagocytosis by human PMNs
(Pascual et al., 1990). A short exposure to
vancomycin increased the susceptibility of
Enterococcus faecalis to PMNs (Bayer & Tu,
1990). The combination of ampicillan/sulbac-
tam enhanced the suscepbility of Staphylococ-
cus aureus to phagocytosis by PMNs, in
contrast, and probably due to low intracellular
penetration of /?-lactams, the same combi-
nation displayed no significant antimicrobial
effect against the bacterium when 'it was
intracellularly located, within the PMNs
(Pascual et al., 1991). Short exposure of
Pseudomonas aeruginosa to supra-MIC concen-
trations of amikacin increased killing by PMNs
even in absence of opsonization (Bayer et al.,
1991).
One possible explanation for the changes
in bacteria-PMN interactions would be that
the antibiotic induces modifications to the cell
surface which enhance bacterial susceptibility
to phagocytosis or intracellular killing. Sup-
porting this theory are the morphological
changes observed in bacteria in relation to
PAE. Lorian, Ernst & Amaral (1989), using
phase contrast microscopy to follow the
bacterial morphology of E. coli after exposure
to ampicillin and ciprofloxacin observed rapid
filamentation of bacteria. Transmission elec-
tron microscopy showed that, during PAE,
dicloxacillin increased the number of cross-
walls and rifampicin produced cell wall
thickening in S. aureus while intracellular
electron dense aggregates were seen in P.
aeruginosa after exposure to imipenem
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(Gottfredsson et al., 1993). Morphological
alterations, notably enlargement, were ob-
served in S. aureus exposed to macrolides for
2h (Watanable et al., 1992). 0-Lactam
antibiotics with high affinity for PBP2 (such as
imipenem) cause a prolonged PAE on Gram-
negative bacteria as well as spheroplast
prolactin (Gudmundsson, Vogelman & Craig,
1986). In E. coli filamentous shapes occur after
treatment with enoxacin and ciprofloxacin for
1 h; spheroplasts were observed after treatment
with imipenem for 2 h (Hanberger et al., 1993).
Other studies suggest that the PAE may have
an impact on toxin and bacterial enzyme
production, which, in turn may affect the host.
Guan & Burnham (1992) investigated extra-
and intracellular-haemolysin activity in E. coli
during PAE phase. Following exposure to
and removal of quinolone, the extracellular
haemolytic activity of E. coli decreased
significantly for at least 2 h, whereas intracellu-
lar activity was adversely affected for only 1 h.
Thus, the production of haemolysin, but not
its export from the bacterium was thought
to be affected during the PAE phase. We
have demonstrated that roxithromycin inhibits
haemolysin production by 5. pyogenes during
the PAE phase and beyond (Shibl, Ramadan &
Tawfik, 1994).
Adherence of treated bacteria is also altered
during the PAE phase. Bacterial adherence is
influenced by the net surface charge and/or
specific binding arrangement by host factors
and by strain variation. During the PAE phase,
the residual antibiotic may cause leakage of
bacterial adhesins 1 (/J-lactams) or may
suppress the formation and expression of
adhesins (aminoglycosides) (Lorian, 1991).
E. coli treated with subinhibitory concen-
trations of ampicillin attach less well than
untreated control bacteria in contrast to those
exposed to chloramphenicol or nitrofurantoin
(Sandberg, Stenqvist & Svanborg-Eden, 1979).
We have also found that cell surface charge
(hydrophobic/hydrophilic) of streptococci to
hydrocarbon is altered after exposure to
macrolides (Ramadan et al., 1994; Shibl et al.,
1994). The decrease in hydrophobicity was
unrelated to inhibition of growth and may
be explained on the basis that macrolides
inhibit adhesin synthesis in streptococci (Shibl,
1985).
Further work is needed to clarify the possible
impact of PAE in the clinical situation. The
concept of PAE should not only be considered
as prolonged suppression of bacterial growth
but also as a potential inducer of decreased
microbial virulence which may directly or
indirectly influence the host-parasite relation-
ship.
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Sir,
Numerous pyrimidine and purine analogues
were synthesized in the late 1940s as potential
nucleic acid antagonists. Particular interest was
devoted to antagonists of thymine. It was
quickly realized that the 2,4-diaminopytimi-
dines inhibit folic acid utilization and that
this was a general property of all of these
compounds (Hitchings et al., 1950; Hitchings,
1989).
It was recognised that the 3,4,5-trimethoxyl-
diaminopyrimidine-derivative was outstanding
for its breadth of antibacterial activity.
Consequently it was selected for detailed study
and clinical trials in 1959 (Roth et al., 1962) and
given the name trimethoprim. Subsequently a
3,4-dimethoxy-5-bromo derivative was also
found to be active. The role of bromine
substitution on the benzyl-ring of trimethoprim
was later confirmed with an analogue in which
the 4-methoxy group, instead of being in the 5
position, was substituted by this halogen; the
compound was synthesized in 1972 (Kompis
et al., 1980) and named brodimoprim. The effect
of this substitution was to improve the
trimethoprim binding to bacterial DHFR (Then
& Hermann, 1984), providing equivalent or
better antibacterial activity, improving lipid
solubility and the pharmacokinetic behaviour,
and to achieve sufficiently high concentrations
at the infection site (Weidekamm, 1993).
Trimethoprim was put forward as a potentia-
tor of sulphonamides for the treatment of
bacterial infections: sulphamethoxazole was
chosen as the sulphonamide owing matched
half-life of trimethoprim. It was argued that
the combination of sulphamethoxazole and
trimethoprim, later given the name co-trimoxa-
zole in Europe, offered several antimicrobial
advantages (Hitchings, 1989).
Since its introduction in 1968 co-trimoxazole
is still widely used for the treatment of a wide
variety of bacterial infections, toxoplasmosis
and in particular Pneumocystis carinii pneumo-
nia. However, in many circumstances, it is
the trimethoprim moiety of this combination
that is responsible for its clinical effectiveness
owing to increasing bacterial resistance to the
sulphonamide. In fact, the sulphonamide
moiety of the mixture may be disadvantageous
because of a number of adverse reactions and
drug interactions which are more common in
the elderly and chronically ill patients, or in
those receiving prolonged high dose treatment
(Reeves, 1982; Kucers, Bennett & Kemp, 1987;
British National Formulary, 1993; Brumfitt &
Hamilton-Miller, 1994). Trimethoprim became
available for use as a single drug in 1973 and
brodimoprim 20 years later (Periti et al., 1993).
Trimethroprim alone has been shown in
clinical trials to be as effective and better
